Los Angeles Capital Management LLC Lowers Position in Replimune Group, Inc. (NASDAQ:REPL)

Los Angeles Capital Management LLC lowered its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 41.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,547 shares of the company’s stock after selling 24,040 shares during the period. Los Angeles Capital Management LLC owned approximately 0.05% of Replimune Group worth $418,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in REPL. Bank of New York Mellon Corp increased its holdings in shares of Replimune Group by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company’s stock worth $2,113,000 after buying an additional 11,893 shares during the last quarter. New York State Common Retirement Fund increased its stake in Replimune Group by 260.8% during the fourth quarter. New York State Common Retirement Fund now owns 43,204 shares of the company’s stock worth $523,000 after acquiring an additional 31,231 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Replimune Group by 8.3% in the 4th quarter. Rhumbline Advisers now owns 95,465 shares of the company’s stock worth $1,156,000 after purchasing an additional 7,317 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Replimune Group by 24.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock valued at $198,000 after purchasing an additional 3,177 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock worth $318,000 after purchasing an additional 3,374 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

REPL has been the topic of several research reports. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. BMO Capital Markets lifted their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Jefferies Financial Group upped their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, HC Wainwright raised their price objective on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Replimune Group currently has an average rating of “Buy” and an average target price of $19.43.

Replimune Group Stock Performance

Replimune Group stock opened at $12.12 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The firm’s fifty day moving average price is $12.79 and its 200 day moving average price is $12.02. The company has a market capitalization of $933.42 million, a price-to-earnings ratio of -3.95 and a beta of 1.30. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, research analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.80% of the stock is owned by company insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.